key: cord-0844806-9gblwh6f
authors: Atmosudigdo, Indriwanto Sakidjan; Pranata, Raymond; Lim, Michael Anthonius; Henrina, Joshua; Yonas, Emir; Vania, Rachel; Radi, Basuni
title: Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression
date: 2021-02-08
journal: J Clin Exp Hepatol
DOI: 10.1016/j.jceh.2021.01.007
sha: 4b43ce036373d91e02fffc35cfcb47e116acbd3e
doc_id: 844806
cord_uid: 9gblwh6f

OBJECTIVE: This systematic review and meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association. METHODS: A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8 October 2020. This study's main outcome is a poor composite outcome, comprising of mortality and severe COVID-19. RESULTS: There were 9 studies with 3,663 patients. The prevalence of dyslipidemia in this pooled analysis was 18% (4%-32%). Dyslipidemia was associated with increased composite poor outcome (RR 1.39 [1.02, 1.88], p=0.010; I(2): 56.7%, p=0.018). Subgroup analysis showed that dyslipidemia was associated with severe COVID-19 (RR 1.39 [1.03, 1.87], p=0.008; I(2): 57.4%, p=0.029). Meta-regression showed that the association between dyslipidemia and poor outcome varies by age (coefficient: -0.04, p=0.033), male gender (coefficient: -0.03, p=0.042), and hypertension (coefficient: -0.02, p=0.033), but not diabetes (coefficient: -0.24, p=0.135) and cardiovascular diseases (coefficient: -0.01, p=0.506). Inverted funnel-plot was relatively symmetrical. Egger’s test indicates that the pooled analysis was not statistically significant for small-study effects (p=0.206). CONCLUSION: Dyslipidemia potentially increases mortality and severity of COVID-19. The association was stronger in patients with older age, male, and hypertension. PROSPERO REGISTRATION NUMBER: CRD42020213491

Coronavirus disease 2019 (COVID- 19) is rapidly increasing and threatens to overwhelm healthcare systems, especially in developing countries. 1 Potential prognostic factors such as comorbidities [2] [3] [4] [5] [6] and laboratory results [7] [8] [9] facilitate risk stratification and allocation of highrisk patients to receive more intensive monitoring. This is especially important in developing countries, which may struggle due to a lack of medical resources.

Approximately 30-60% of the population is affected by dyslipidemia, making it one of the most prevalent conditions in healthy people. [10] [11] [12] Thus, it is potentially one of the most common comorbidities in patients with COVID-19. The metabolic and lipid profile may even worsen due to less activity and imbalanced diet during the pandemic. However, the evidence on whether dyslipidemia influences the prognosis of COVID-19 remains contradictory. [13] [14] [15] [16] This meta-analysis aimed to evaluate whether dyslipidemia affects the mortality and severity of COVID-19, we also aimed to evaluate whether other comorbidities influence the association.

This study is reported in accordance to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines. This study is registered in the PROSPERO (CRD42020213491).

The inclusion criteria were studies reporting COVID-19 patients along with the information on dyslipidemia and mortality/severity/progression of COVID-19 disease.

We excluded preprints, letters, conference abstracts, review articles, editorials/opinion, and case reports/series to reduce bias. J o u r n a l P r e -p r o o f

A systematic literature search using PubMed, Embase, and EuropePMC was performed on 8

October 2020. The PubMed search keywords was ((dyslipidemia) OR (hyperlipidemia)) AND ((severity) OR (mortality)) AND ((COVID-19) OR (2019-nCoV) OR (coronavirus) OR (SARS-CoV-2)). After the initial search, we remove duplicates; then, the titles and abstracts were screened and evaluated for their eligibility by two independent authors. The literature searchers are experienced in performing systematic reviews.

Two authors independently conducted data extraction with the aid of standardized extraction forms comprised of the first author, year of publication, study design, age, gender, diabetes mellitus, hypertension, cardiovascular disease, smoking, obesity, liver disease, and outcome of interest. The factors chosen were based on the possibility that they may confound the association between dyslipidemia and the main outcome.

The key exposure in this study was dyslipidemia, defined as dyslipidemia as comorbidity that was diagnosed based on medical history or medical records. Other variables such as diabetes mellitus, hypertension, cardiovascular disease, smoking, obesity, and liver disease were also based on diagnosis from medical history or medical records. considered as statistically significant. Inter-study heterogeneity was assessed using Isquared (I2) and Cochrane Q test, with a value of >50% or p-value <0.10 indicates significant heterogeneity. Subgroup analysis was performed for severe COVID-19. Random-effects meta-regression with Restricted-maximum likelihood method was performed using one covariate at a time for age, gender, hypertension, diabetes mellitus, cardiovascular disease, smoking, and obesity. Egger's test was performed to assess small-study effects. Funnel-plot analysis was used to assess the risk of publication bias.

Preliminary several databases search yielded 1497 articles. After subsequent exclusion of duplicates, the remaining articles for the title and abstract screening were 1367 articles.

Then, a total of 1350 articles were excluded, with the remaining articles underwent full-text eligibility assessment. Finally, out of 17 studies assessed for full-text eligibility, nine studies with 3,663 patients were included in the meta-analysis. 13 

The mean NOS of the included studies was 8 +/-0.86, indicating high-quality studies.

Inverted funnel-plot was relatively symmetrical [ Figure 4 ]. Egger's test indicates that the pooled analysis was not statistically significant for small-study effects (p=0.206).

Meta-analysis showed that dyslipidemia potentially increases severity and mortality associated with COVID-19. The association was affected by age, male, and hypertension.

However, this association is limited by the lack of details regarding comorbidities and medications consumption among the patients.

Meta-regression analysis showed that older age, male, and hypertension affect the association between dyslipidemia and poor outcome. This may indicate that the association may be due to other conditions accompanying dyslipidemia rather than dyslipidemia itself. reported that dyslipidemia as an independent predictor of mortality. 19 Obesity and chronic liver disease, including fatty liver disease, may affect the association between dyslipidemia and poor outcome; because both obesity and fatty liver disease are associated with poor prognosis. [24] [25] [26] However, meta-regression analysis was not possible because only three studies were reporting chronic liver disease, and one study reporting obesity.

Plasma lipids and lipoproteins measurement, such as low-density lipoprotein (LDL), verylow-density lipoprotein (vLDL), high-density lipoprotein (HDL), and triglycerides (TG), is a key component in managing the risk of cardiovascular diseases (CVD). Excessive body mass index (BMI) is an independent risk factor for severe COVID-19. A dose-response metaanalysis reported that the risk for composite poor outcome increased by 5% for every 5 kg/mg 2 increase in BMI. 6 Obese individuals are at a higher risk of developing dyslipidemia, insulin resistance, diabetes mellitus, hypertension, CVD and cerebrovascular disease, which are well-known predictor of poor prognosis in COVID-19 patients. 2,3,5,27 Furthermore, the lack of physical inactivity (sedentary lifestyle) in individuals with obesity and dyslipidemia during the pandemic may further undermine their immunity and put them at higher risk of contracting COVID-19. 28, 29 The presence of coexisting diseases, including cardiac disease, pulmonary disease, chronic kidney disease, liver injury, and orthopedic injuries, are also associated with worse outcomes in patients with COVID-19. [30] [31] [32] [33] [34] Excessive immune system activation is often found in severe COVID-19 leading to various complications, such as respiratory failure, multi-organ dysfunction, coagulopathy, and ultimately death. 

immunity with further accumulation of eicosanoids, including thromboxane B2 (TXB 2 ), prostaglandin E2 (PGE 2 ), leukotriene B4 (LTB 4 ), and lipoxin A4 (LXA 4 ). 36 The increased eicosanoids and hypercoagulable state in patients with COVID-19 may contribute to the development of life-threatening complications and eventual death.

The ongoing inflammatory processes result in HDL-related apolipoproteins' modulation, causing increased serum amyloid protein A and decreased apolipoprotein (Apo) A-I, ApoM, and ApoE, which negatively impacts the antioxidant, anti-inflammatory, and immunomodulatory roles of HDL. 37, 38 It is known that HDL acts to stimulate reversecholesterol transport from the peripheral parts to the liver, while also enhance immune system modulation and help to control infectious diseases. Apart from their antioxidant, antithrombotic, and immunomodulatory roles, HDL have a high binding affinity and may neutralize pathogen-associated lipids that mediate an exaggerated immune response in sepsis. 36 Antioxidant and anti-inflammatory properties of HDL are markedly reduced during infections such as in influenza and human immunodeficiency virus infection. 39, 40 In the context COVID-19, low total cholesterol, LDL-C, and HDL-C increases COVID-19 severity and its associated mortality, while plasma TG is often elevated during infection and inflammation. [41] [42] [43] Inflammation alters the composition of HDL apolipoprotein, but the exact mechanism for the phenomenon is currently unknown. The imbalances in the antioxidant mechanism results in oxHDL modification via intracellular lectin-like oxLDL (LOX-1) receptor. Moreover, the extracellular portion of LOX-1, serum-soluble form (sLOX-1), also promotes interaction among the oxidized lipids and circulating macrophages, promoting the release of IL-6, IL-19, and tumor necrosis factor-alpha (TNF-α). Exaggerated inflammatory response and oxidative stress, coupled with inactivation of enzyme paraoxonase 1 (PON1) in HDL, further stimulates lipid oxidation, which further compromise HDL function. 36 Low PON1 activity was shown to be associated with poor prognosis in patients with cardiovascular diseases and was reported to be reduced in various inflammatory and infectious diseases. 44 The overdevelopment of oxHDL and oxLDL, which are potent oxidized LDL scavenger receptor (LOX-1) activators, stimulates further inflammatory processes that exacerbate tissue injury. This cycle leads to changes in the transport of lipoprotein and disruption of the properties. 36 The use of statins can be considered, given its immunomodulatory properties and their interactions with TLR on host cell membrane. Statin use was shown to reduce the risk of adverse outcomes in COVID-19 patients. 47 Exercise should be encouraged during the pandemic, a worsening metabolic and lipid profile not only increases the risk for severe COVID-19, but may also increase the risk of acute cardiovascular events. These events may lead to epidemic of cardio-cerebrovascular diseases post-pandemic. 27, 48, 49 

The majority of the studies in this meta-analysis were retrospective in nature. There was lack of data in the drugs used in these study population. Most of the studies did not report the TG, LDL, and HDL; the extent of dyslipidemia may affect the prognosis. Most of the studies did not report obesity, which is important in patients with dyslipidemia. Additionally, the included studies were not geared towards evaluating dyslipidemia's effect on COVID-19; J o u r n a l P r e -p r o o f 

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression

Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression

The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression

Body Mass Index and Outcome in Patients with COVID-19: A Dose-Response Meta-Analysis. Diabetes Metab

Lymphopenia in severe coronavirus disease-2019 (COVID-19): review and meta-analysis

Prevalence of dyslipidemia according to the nutritional status in a representative sample of São Paulo

Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): Gender, ethnicity, and coronary artery calcium

Prevalence and risk factors for dyslipidemia among adults in rural and urban China: Findings from the China National Stroke Screening and prevention project (CNSSPP)

A Novel Scoring System for Prediction of Disease Severity in COVID-19

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Determinants of COVID-19 disease severity in patients with underlying rheumatic disease

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Risk factors for disease progression in COVID-19 patients

Hepatic Steatosis Is Associated with Increased Disease Severity and Liver Injury in Coronavirus Disease-19

Body Mass Index as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York

Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis

A wave of non-communicable diseases following the COVID-19 pandemic

Sports activities during any pandemic lockdown

Exercise Addiction and COVID-19-Associated Restrictions

Effect of heart failure on the outcome of COVID-19 -A meta analysis and systematic review

Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19

The Importance of COVID-19 Prevention and Containment in Hemodialysis Unit

The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis

Coronavirus disease 2019 (COVID-19) markedly increased mortality in patients with hip fracture -A systematic review and meta-analysis

C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a metaanalysis

COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches

COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and

Antiinflammatory properties of HDL

The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B

High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection

Low Serum Cholesterol Level Among Patients with COVID-19 Infection in Wenzhou

Hypolipidemia is associated with the severity of COVID-19

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host

Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis

OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling

Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis

Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients

Out-of-hospital cardiac arrest prognosis during the COVID-19 pandemic

Impact of the Coronavirus Disease Pandemic on the Number of Strokes and Mechanical Thrombectomies: A Systematic Review and Meta-Analysis

Basics of meta-analysis